Our Pricing

Can I Get Mounjaro on NHS? Your Complete UK Guide

If you're asking can I get Mounjaro on NHS, you're not alone—thousands of UK patients are exploring access to this breakthrough weight loss treatment. While Mounjaro (tirzepatide) is MHRA-licensed in the UK, NHS availability remains extremely limited, with strict eligibility criteria and substantial waiting lists in most areas.

Current NHS Availability of Mounjaro in the UK

Mounjaro received its UK marketing authorisation from the MHRA in September 2023, but NHS commissioning decisions are made by regional Integrated Care Boards (ICBs) rather than nationally [1]. As of 2025, most NHS trusts have not yet added Mounjaro to their formularies due to budget constraints and ongoing NICE appraisal processes.

Where NHS Mounjaro is available, access is typically restricted to specialist weight management services with eligibility criteria far stricter than private prescribing guidelines. Patients usually require a BMI above 35 with significant comorbidities, documented evidence of previous weight loss attempts, and referral through tier 3 or tier 4 obesity services [2].

Waiting times for NHS specialist weight management appointments commonly exceed 12-18 months in many regions, with additional delays before medication initiation. This has led many eligible patients to explore private prescription options to begin treatment sooner.

NHS Mounjaro Eligibility Criteria Explained

Even in areas where NHS Mounjaro prescribing exists, strict clinical criteria apply. Most NHS services require a BMI of 35 kg/m² or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease [2].

Additional requirements typically include documented participation in a structured weight management programme for at least 6-12 months, evidence of dietary and lifestyle modification attempts, and psychological assessment to ensure treatment readiness. Patients with certain contraindications—including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2—are excluded entirely [1].

Your GP cannot directly prescribe Mounjaro on the NHS for weight loss in most areas. Referral to a specialist obesity service is required, where a multidisciplinary team assesses suitability and monitors treatment response through regular follow-up appointments.

Why NHS Access Remains Limited

The primary barrier to NHS Mounjaro availability is cost. At current wholesale prices, a year's treatment represents a significant investment per patient, which many cash-constrained ICBs cannot accommodate within existing budgets. NICE guidance on tirzepatide for weight management is still under development, and without a positive technology appraisal, most NHS trusts remain cautious about widespread commissioning [2].

How Mounjaro Works: The Science Behind Tirzepatide

Mounjaro contains tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK [1]. This dual mechanism distinguishes it from single-pathway treatments like semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda).

By activating both GIP and GLP-1 receptors, tirzepatide enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways. In the SURPASS-3 trial, patients receiving the 15mg maintenance dose achieved an average 22.5% body weight reduction over 72 weeks—significantly greater than comparator treatments [1][3].

The SURMOUNT-1 trial, which specifically examined tirzepatide for weight management in adults without diabetes, demonstrated average weight loss of 20.9% with the 15mg dose compared to 3.1% with placebo over 72 weeks [3]. These results represent the highest efficacy seen in any obesity pharmacotherapy trial to date.

Private Prescription Options: Accessing Mounjaro Without NHS

Given limited NHS availability, private prescription through UK-registered online pharmacies offers a faster, more accessible route to Mounjaro for eligible patients. At Cured Pharmacy, Mounjaro is available from £135.00 following a free online consultation with a UK-registered prescriber [4].

Private prescribing eligibility criteria are clinically appropriate but less restrictive than NHS pathways. Most UK prescribers consider Mounjaro for adults with a BMI of 30 kg/m² or higher, or 27 kg/m² with at least one weight-related comorbidity. The same contraindications apply as NHS prescribing, ensuring patient safety remains paramount.

The private consultation process at Cured Pharmacy takes under three minutes and is completed entirely online. A UK prescriber reviews your medical history, current medications, and weight loss goals to determine suitability. If approved, your prescription is dispensed from our GPhC-registered pharmacy (registration number 9012511) with discreet next-day delivery across the UK.

Transparent Pricing and Ongoing Support

Unlike some providers, Cured Pharmacy displays upfront pricing before consultation—no hidden fees or surprise charges. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures every patient receives clear guidance on dosing schedules, injection technique, and managing potential side effects. Ongoing prescriber support is included with every treatment plan.

Comparing Mounjaro to Other Weight Loss Treatments

While Mounjaro demonstrates superior weight loss outcomes in clinical trials, other licensed treatments may be appropriate depending on individual circumstances, budget, and clinical history. Wegovy (semaglutide) is a once-weekly GLP-1 receptor agonist that achieved average weight loss of 14.9% over 68 weeks in the STEP 1 trial [5].

Saxenda (liraglutide) requires daily injections and typically produces more modest weight loss—around 8% over 56 weeks in clinical trials [6]. Orlistat-based treatments (Xenical, Orlos, Alli) work through a different mechanism by blocking dietary fat absorption, with average weight loss of 3-5% when combined with dietary modification.

Your prescriber will consider factors including your weight loss goals, previous treatment responses, injection frequency preference, budget, and any existing medical conditions when recommending the most suitable option. Many patients who don't meet criteria for GLP-1 treatments may still benefit from orlistat or structured lifestyle programmes.

What to Expect: Mounjaro Dosing and Side Effects

Mounjaro treatment follows a gradual dose escalation schedule to minimise gastrointestinal side effects. Most patients start with 2.5mg once weekly for four weeks, then increase to 5mg weekly. Further increases to 7.5mg, 10mg, 12.5mg, or 15mg occur at four-week intervals based on individual response and tolerability [1].

Common side effects include nausea, diarrhoea, vomiting, constipation, and reduced appetite—typically most pronounced during dose escalation phases and improving with continued use [1][3]. Serious but rare risks include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking other glucose-lowering medications).

Clinical trials showed approximately 5-10% of patients discontinued tirzepatide due to gastrointestinal adverse events [3]. Your prescriber will provide detailed guidance on managing side effects, recognising warning signs requiring medical attention, and optimising treatment adherence. Regular follow-up ensures dose adjustments are made appropriately as you progress through your weight loss journey.

Injection Technique and Storage

Mounjaro KwikPens are pre-filled, single-use devices designed for subcutaneous injection into the abdomen, thigh, or upper arm. Each pen contains one weekly dose and should be stored in a refrigerator between 2°C and 8°C until use. Detailed injection instructions are provided with every prescription, and our pharmacy team is available to answer technique questions throughout your treatment.

Scientific References

1. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. Retrieved from https://www.medicines.org.uk/emc/product/14395
2. National Institute for Health and Care Excellence. (2024). Obesity: identification, assessment and management [CG189]. NICE. Retrieved from https://www.nice.org.uk/guidance/cg189
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. General Pharmaceutical Council. (2024). Registered Pharmacies: Cured Pharmacy [Registration Number 9012511]. GPhC Register. Retrieved from https://www.pharmacyregulation.org/
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
6. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine that may not be suitable for everyone. Individual results vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.